Spruce Biosciences (SPRB) Stock Price, News & Analysis

Company Overview

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.06 to $0.32
• 52-Week Range: $0.06 to $0.74
• Volume: 223,611 shs
• Average Volume: 721,478 shs
• Market Capitalization: $2.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.17
• Consensus Rating: Hold

Spruce Biosciences Stock Analysis - MarketRank™

Spruce Biosciences scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Spruce Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Spruce Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Spruce Biosciences are expected to grow in the coming year, from ($1.00) to ($0.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spruce Biosciences is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spruce Biosciences is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Spruce Biosciences has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SPRB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spruce Biosciences does not currently pay a dividend.

Dividend Growth

Spruce Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for SPRB.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for SPRB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spruce Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.10% of the stock of Spruce Biosciences is held by insiders.

Percentage Held by Institutions

91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SPRB Stock Analysis - Frequently Asked Questions

How have SPRB shares performed this year?

Spruce Biosciences' stock was trading at $0.42 on January 1st, 2025. Since then, SPRB shares have decreased by 83.4% and is now trading at $0.0698.
View the best growth stocks for 2025 here.

How were Spruce Biosciences' earnings last quarter?

Spruce Biosciences, Inc. (NASDAQ:SPRB) posted its quarterly earnings results on Tuesday, April, 15th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.37. The company earned $0.55 million during the quarter, compared to analyst estimates of $0.50 million. Spruce Biosciences had a negative trailing twelve-month return on equity of 62.10% and a negative net margin of 555.23%.

When did Spruce Biosciences IPO?

Spruce Biosciences (SPRB) raised $75 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets served as the underwriters for the IPO.

How do I buy shares of Spruce Biosciences?

Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Spruce Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Spruce Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE), Meta Platforms (META) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 4/15/2025
• Today: 6/01/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRB
• CIK: 1683553
• Web: www.sprucebiosciences.com
• Phone: 415-655-4168
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.17
• High Stock Price Target: $3.00
• Low Stock Price Target: $0.50
• Potential Upside/Downside: +3,004.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.92 million
• Net Margins: -555.23%
• Pretax Margin: -555.23%
• Return on Equity: -62.10%
• Return on Assets: -47.49%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.36
• Quick Ratio: 5.36

Sales & Book Value

• Annual Sales: $4.91 million
• Price / Sales: 0.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.88 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 42,231,000
• Free Float: 37,544,000
• Market Cap: $2.95 million
• Optionable: Optionable
• Beta: 2.49